Eterna Therapeutics Stock Price To Sales
| ERNA Stock | USD 2.03 0.09 4.25% |
Eterna Therapeutics fundamentals help investors to digest information that contributes to Eterna Therapeutics' financial success or failures. It also enables traders to predict the movement of Eterna Stock. The fundamental analysis module provides a way to measure Eterna Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eterna Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 126.60 | 132.93 |
Eterna | Price To Sales |
Eterna Therapeutics Company Price To Sales Analysis
Eterna Therapeutics' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Eterna Therapeutics Price To Sales | 178.22 X |
Most of Eterna Therapeutics' fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eterna Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Eterna Price To Sales Driver Correlations
Understanding the fundamental principles of building solid financial models for Eterna Therapeutics is extremely important. It helps to project a fair market value of Eterna Stock properly, considering its historical fundamentals such as Price To Sales. Since Eterna Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Eterna Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Eterna Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Eterna Price To Sales Historical Pattern
Today, most investors in Eterna Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Eterna Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's price to sales growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Eterna Therapeutics price to sales as a starting point in their analysis.
Eterna Therapeutics Price To Sales |
| Timeline |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Eterna Price To Sales Ratio
Price To Sales Ratio |
|
Based on the latest financial disclosure, Eterna Therapeutics has a Price To Sales of 178 times. This is much higher than that of the Biotechnology sector and 81.1% higher than that of the Health Care industry. The price to sales for all United States stocks is notably lower than that of the firm.
Eterna Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eterna Therapeutics' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eterna Therapeutics could also be used in its relative valuation, which is a method of valuing Eterna Therapeutics by comparing valuation metrics of similar companies.Eterna Therapeutics is currently under evaluation in price to sales category among related companies.
Eterna Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Eterna Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Eterna Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Eterna Fundamentals
| Return On Equity | -3.02 | ||||
| Return On Asset | -0.36 | ||||
| Operating Margin | (339.12) % | ||||
| Current Valuation | 46.98 M | ||||
| Shares Outstanding | 5.41 M | ||||
| Shares Owned By Insiders | 39.31 % | ||||
| Shares Owned By Institutions | 7.38 % | ||||
| Number Of Shares Shorted | 34.2 K | ||||
| Price To Book | 5.43 X | ||||
| Price To Sales | 178.22 X | ||||
| Revenue | 68 K | ||||
| EBITDA | (19.55 M) | ||||
| Net Income | (21.67 M) | ||||
| Cash And Equivalents | 19.41 M | ||||
| Cash Per Share | 6.60 X | ||||
| Total Debt | 41.84 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 3.08 X | ||||
| Book Value Per Share | 0.41 X | ||||
| Cash Flow From Operations | (20.41 M) | ||||
| Short Ratio | 6.32 X | ||||
| Earnings Per Share | (4.08) X | ||||
| Price To Earnings To Growth | (0.03) X | ||||
| Target Price | 3.0 | ||||
| Beta | 8.21 | ||||
| Market Capitalization | 11.47 M | ||||
| Total Asset | 49.13 M | ||||
| Retained Earnings | (186.98 M) | ||||
| Working Capital | 3.03 M | ||||
| Net Asset | 49.13 M |
About Eterna Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eterna Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eterna Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eterna Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| C | Citigroup | |
| CRM | Salesforce | |
| MSFT | Microsoft |
Check out Eterna Therapeutics Piotroski F Score and Eterna Therapeutics Altman Z Score analysis. For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Eterna Stock analysis
When running Eterna Therapeutics' price analysis, check to measure Eterna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eterna Therapeutics is operating at the current time. Most of Eterna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Eterna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eterna Therapeutics' price. Additionally, you may evaluate how the addition of Eterna Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is Eterna Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eterna Therapeutics. If investors know Eterna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eterna Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.08) | Revenue Per Share 0.013 | Return On Assets (0.36) | Return On Equity (3.02) |
The market value of Eterna Therapeutics is measured differently than its book value, which is the value of Eterna that is recorded on the company's balance sheet. Investors also form their own opinion of Eterna Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Eterna Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eterna Therapeutics' market value can be influenced by many factors that don't directly affect Eterna Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eterna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eterna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eterna Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.